![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
L Simon, B Ghaleh, L Puybasset, JF Giudicelli and A Berdeaux
Departement de Pharmacologie, Faculte de Medecine Paris-Sud, Le Kremlin- Bicetre, France.
The effects of (7,8-dimethoxy 3-[3-([(1S)-(4,5-dimethoxybenzocyclobutan- 1-yl)methyl]methylamino) - propyl]1,3,4,5-tetrahydro-2H-benzapin 2-one hydrochloride) (S 16257), a new bradycardic agent acting through inhibition of the hyperpolarization-activated I(f) current in the sino- atrial node, on arterial blood pressure, cardiac output, left ventricular pressure and dP/dt, epicardial coronary artery diameter and coronary blood flow velocity were investigated at graded doses (0.1 to 1 mg/kg) and compared to those of propranolol (1 mg/kg) and saline in chronically instrumented conscious dogs. At rest, S 16257 induced a dose-dependent bradycardia that was significant at 0.5 (-16% +/- 3%) and 1 mg/kg (-23% +/- 3%). At 0.5 mg/kg, S 16257 decreased both resting HR and treadmill exercise-induced tachycardia to a similar extent as propranolol. However, in contrast to propranolol, S 16257 (0.5 mg/kg) did not affect the increase in mean coronary blood flow velocity and the decrease in coronary vascular resistance observed during a control exercise performed under saline. In addition, S 16257 did not affect resting epicardial coronary artery diameter and only attenuated its increase during exercise, whereas propranolol reduced it at rest and maintained a significant constriction of these large vessels throughout the exercise period. Propranolol, but not S 16257, decreased left ventricular dP/dt at each stage of exercise.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  R. Ferrari, C. Ceconi, and G. Guardigli Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F7 - F10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Mangoni and J. Nargeot Genesis and Regulation of the Heart Automaticity Physiol Rev, July 1, 2008; 88(3): 919 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ciobotaru, M. Heimburger, L. Louedec, C. Heymes, R. Ventura-Clapier, P. Bedossa, B. Escoubet, J.-B. Michel, J.-J. Mercadier, and D. Logeart Effect of Long-Term Heart Rate Reduction by If Current Inhibition on Pressure Overload-Induced Heart Failure in Rats J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Heusch and R. Schulz The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F8 - F14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rosen, A. Bucchi, and R. B. Robinson If modulation: perspectives in clinical medicine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D3 - D8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Camm How does pure heart rate lowering impact on cardiac tolerability? Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D9 - D15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg and D. Tchetche Pharmacologic management of stable angina: role of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D16 - D23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif and C. Berry From coronary artery disease to heart failure: potential benefits of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D24 - D29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. Leoni, C. Marionneau, S. Demolombe, S. L. Bouter, M. E. Mangoni, D. Escande, and F. Charpentier Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle Physiol Genomics, December 14, 2005; 24(1): 4 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif, I. Ford, M. Tendera, M. G. Bourassa, K. Fox, and for the INITIATIVE Investigators Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina Eur. Heart J., December 1, 2005; 26(23): 2529 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Borer Heart rate slowing by If inhibition: therapeutic utility from clinical trials Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif Ivabradine in clinical practice: benefits of If inhibition Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H29 - H32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fox Future perspectives of If inhibition in various cardiac conditions Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H33 - H36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mulder, S. Barbier, A. Chagraoui, V. Richard, J. P. Henry, F. Lallemand, S. Renet, G. Lerebours, F. Mahlberg-Gaudin, and C. Thuillez Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure Circulation, April 6, 2004; 109(13): 1674 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Monnet, P. Colin, B. Ghaleh, L. Hittinger, J.-F. Giudicelli, and A. Berdeaux Heart rate reduction during exercise-induced myocardial ischaemia and stunning Eur. Heart J., April 1, 2004; 25(7): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Colin, B. Ghaleh, X. Monnet, L. Hittinger, and A. Berdeaux Effect of Graded Heart Rate Reduction with Ivabradine on Myocardial Oxygen Consumption and Diastolic Time in Exercising Dogs J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 236 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.P. Vilaine, C. Thollon, N. Villenueve, and J.L. Peglion Procoralan, a new selective If current inhibitor Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G26 - G35. [Abstract] [PDF]
|
|
|
|
|
|
K. Fox Ivabradine -- a selective and specific If inhibitor: efficacy and safety in stable angina Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G36 - G45. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Borer, K. Fox, P. Jaillon, G. Lerebours, and for the Ivabradine Investigators Group Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial Circulation, February 18, 2003; 107(6): 817 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Colin, B. Ghaleh, X. Monnet, J. Su, L. Hittinger, J.-F. Giudicelli, and A. Berdeaux Contributions of heart rate and contractility to myocardial oxygen balance during exercise Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H676 - H682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Colin, B. Ghaleh, L. Hittinger, X. Monnet, M. Slama, J.-F. Giudicelli, and A. Berdeaux Differential effects of heart rate reduction and beta -blockade on left ventricular relaxation during exercise Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H672 - H679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Monnet, B. Ghaleh, P. Colin, O. P. de Curzon, J.-F. Giudicelli, and A. Berdeaux Effects of Heart Rate Reduction with Ivabradine on Exercise-Induced Myocardial Ischemia and Stunning J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bel, L. P. Perrault, B. Faris, C. Mouas, J.-P. Vilaine, and P. Menasche Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations Ann. Thorac. Surg., July 1, 1998; 66(1): 148 - 152. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
